Improved DC Voltage Utilization of the Star-Connected Cascaded H-Bridge Converter

by Tsai, Sheng Yang, 蔡昇洋
Published 2015

Pulmonary Venous Obstruction in Cancer Patients

by Chuang-Chi Liaw, Hung Chang, Tsai-Sheng Yang, Ming-Sheng Wen
Published 2015-01-01

Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild‐type KRAS exon 2 metastatic colorectal cancer

by Hung‐Chih Hsu, Yu‐Chun Liu, Chuang‐Wei Wang, Wen-Chi Chou, Yu-Jen Hsu, Jy-Ming Chiang, Yung-Chang Lin, Tsai-Sheng Yang
Published 2019-07-01

Real-World Effectiveness of Adjuvant Oxaliplatin Chemotherapy in Stage III Colon Cancer: A Controlled Interrupted Time Series Analysis

by Wen-Kuan Huang, Wen-Kuan Huang, Wen-Kuan Huang, Hung-Chih Hsu, Hung-Chih Hsu, Shu-Hao Chang, Wen-Chi Chou, Wen-Chi Chou, Pei-Hung Chang, Pei-Hung Chang, Sum-Fu Chiang, John Wen-Cheng Chang, John Wen-Cheng Chang, Jen-Shi Chen, Jen-Shi Chen, Tsai-Sheng Yang, Tsai-Sheng Yang, Lai-Chu See, Lai-Chu See, Lai-Chu See
Published 2021-06-01

<i>TP53</i> DNA Binding Domain Mutations Predict Progression-Free Survival of Bevacizumab Therapy in Metastatic Colorectal Cancer

by Hung-Chih Hsu, Jeng-Fu You, Shu-Jen Chen, Hua-Chien Chen, Chien-Yuh Yeh, Wen-Sy Tsai, Hsin-Yuan Hung, Tsai-Sheng Yang, Nina Lapke, Kien Thiam Tan
Published 2019-07-01

Modified biweekly oxaliplatin and capecitabine for advanced gastric cancer: A retrospective analysis from a medical center

by Yung-Chia Kuo, Hao-Tien Liu, Yi-Lun Lin, Yi-Chun Yang, Tsai-Sheng Yang, Chi-Ting Liau, Wen-Chi Shen, Hung-Chih Hsu, Wen-Chi Chou, Jen-Shi Chen
Published 2014-06-01

Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review

by Wen-Chi Chou, Chia-Lin Lee, Tsai-Sheng Yang, Chen-Yang Huang, Wei Teng, Ya-Ting Tseng, Jen-Shi Chen, Yung-Chang Lin, Ming-Mo Hou, Ho-Hsiang Chang, Jason Chia-Hsun Hsieh
Published 2018-02-01

PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients

by Hung-Chih Hsu, Nina Lapke, Shu-Jen Chen, Yen-Jung Lu, Ren-Shiang Jhou, Chien-Yuh Yeh, Wen-Sy Tsai, Hsin-Yuan Hung, Jason Chia-Hsun Hsieh, Tsai-Sheng Yang, Tan Kien Thiam, Jeng-Fu You
Published 2018-09-01

Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan

by Kun-Huei Yeh, Tsai-Sheng Yang, Tzu-Chi Hsu, William Tzu-Liang Chen, Hong-Hwa Chen, Hao-Wei Teng, Bo-Wen Lin, Feng-Che Kuan, Feng-Fan Chiang, Chi-Wei Duann, Ying-Shiuan Li, Meng-Ting Lin, Sabine Fiala-Buskies, Michel Ducreux, Jaw-Yuan Wang
Published 2021-11-01

Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread

by Hung-Chih Hsu, Kuo-Cheng Huang, Wei-Shone Chen, Jeng-Kai Jiang, Shung-Haur Yang, Huann-Sheng Wang, Shih-Ching Chang, Yuan-Tzu Lan, Chun-Chi Lin, Hung-Hsin Lin, Sheng-Chieh Huang, Hou-Hsuan Cheng, Tsai-Sheng Yang, Chien-Chih Chen, Yee Chao, Hao-Wei Teng
Published 2021-07-01